{"id":48519,"date":"2018-09-20T13:07:06","date_gmt":"2018-09-20T13:07:06","guid":{"rendered":"https:\/\/mppt.hu\/project\/2018-szeptember-xx-evfolyam-3-szam\/"},"modified":"2020-10-19T20:25:39","modified_gmt":"2020-10-19T20:25:39","slug":"2018-szeptember-xx-evfolyam-3-szam","status":"publish","type":"project","link":"https:\/\/mppt.hu\/en\/project\/2018-szeptember-xx-evfolyam-3-szam\/","title":{"rendered":"Volume 20, Issue 3, September 2018"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”3.22.3″ custom_padding=”28px|0px|0|0px|false|false”][et_pb_row _builder_version=”3.25″ custom_padding=”27px|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ header_font=”||||||||” header_text_color=”#000000″ header_4_font=”|700||on|||||” header_4_text_align=”center” header_4_text_color=”#000000″ header_4_font_size=”19px” header_4_letter_spacing=”1px”]<\/p>\n

Volume 20, Issue 3, September 2018<\/h4>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” _builder_version=”3.22.3″ custom_padding=”24px|0px|25px|0px|false|false”][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”3.25″][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_blurb title=”Editoral in Hungarian” url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_szerk_ajanlo_honlapra.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”4.6.6″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_szerk_ajanlo_honlapra.pdf” link_option_url_new_window=”on”]<\/p>\n

G\u00e1bor Kov\u00e1cs<\/p>\n

[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” hover_enabled=”0″ border_width_all=”0px” border_width_bottom=”1px” sticky_enabled=”0″]<\/p>\n

\n

A lapsz\u00e1m, amelyet kez\u00e9ben tart, vagy ak\u00e1r a k\u00e9perny\u0151j\u00e9n tanulm\u00e1nyoz a tisztelt olvas\u00f3, az onkol\u00f3giai \u00e9s pszichi\u00e1triai, d\u00f6nt\u0151en affekt\u00edv betegs\u00e9gek komorbidit\u00e1s\u00e1val, diagnosztikai \u00e9s ter\u00e1pi\u00e1s aspektusaival foglalkozik. A magyar szakirodalmat \u00e1ttekintve el\u00e9g kev\u00e9s tanulm\u00e1nyt tal\u00e1lunk, amely a \u201etesti\u201d \u00e9s \u201elelki\u201d betegs\u00e9gek \u00f6sszefu\u0308gg\u00e9s\u00e9vel foglalkozik, pedig \u00e1ltal\u00e1noss\u00e1gban a teljes popul\u00e1ci\u00f3 t\u00f6bb mint fele szenved valamilyen szomatikus betegs\u00e9gben, k\u00f6zu\u0308lu\u0308k kb 30%-n\u00e1l pszichi\u00e1triai probl\u00e9ma is felt\u00e1rhat\u00f3. A n\u00e9pess\u00e9g \u00bc-n\u00e9l fordul el\u0151 pszich\u00e9s megbeteged\u00e9s, k\u00f6zu\u0308lu\u0308k 70%-n\u00e1l mutathat\u00f3 ki szomatikus k\u00f3rfolyamat (1). Ezek az adatok is arra utalnak, hogy a klinikai gyakorlatban nagyobb figyelmet kell szentelnu\u0308nk a komorbid folyamatok felismer\u00e9s\u00e9re, ter\u00e1pi\u00e1j\u00e1ra.<\/h4>\n<\/div>\n

[\/et_pb_toggle][et_pb_blurb title=”Psychological disorders and tumorous diseases” url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_lazary_honlapra.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_lazary_honlapra.pdf” link_option_url_new_window=”on”]<\/p>\n

Judit Laz\u00e1ry<\/p>\n

[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” hover_enabled=”0″ border_width_all=”0px” border_width_bottom=”1px” sticky_enabled=”0″]<\/p>\n

\n
\n

Judit Laz\u00e1ry<\/p>\n

\n

 <\/p>\n

Ny\u00edr\u0151 Gyula OPAI, Budapest<\/em><\/p>\n<\/div>\n

\n
\n

Oncopsychology affects and intensively increasing number of patients due to the growing prevalence of cancers and the rapid development of oncological therapies. The comorbidity between tumorous diseases and psychiatric disorders has been known for a long time but its significance has become outstanding in the recent years. The relationship between these two types of disorders is considerably complex and may have determining consequences for clinical practice therefore dealing with these conditions is a serious challenge for clinicians.
Our knowledge concerning the association of mental illnesses and oncological diseases has been undergoing a significant change in recent years thanks to big data researches and more precise measurements of psychiatric phenotypes. This review provides a summary of the latest epidemiological results related to comorbitiy between mental and oncological illnesses. The novel, more sophisticated studies reinforce the importance of managing comorbid patients in a multidisciplinary team.<\/p>\n

Keywords:<\/strong> oncopsychology, mental illnesses in cancers, psychiatric disorder related cancers,
oncologic and psychiatric comorbidity, dual diagnosis in psychiatric patients<\/p>\n<\/div>\n<\/div>\n

[\/et_pb_toggle][et_pb_blurb title=”Effect of antidepressants in comorbid oncological and depressed patients” url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_kovacs_honlapra.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_kovacs_honlapra.pdf” link_option_url_new_window=”on”]<\/p>\n

G\u00e1bor Kov\u00e1cs 1<\/sup> \u00e9s L\u00e1szl\u00f3 P\u00e9ter2<\/sup><\/p>\n

 <\/p>\n

[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” hover_enabled=”0″ border_width_all=”0px” border_width_bottom=”1px” sticky_enabled=”0″]<\/p>\n

\n
\n

G\u00e1bor Kov\u00e1cs 1<\/sup> \u00e9s L\u00e1szl\u00f3 P\u00e9ter2<\/sup><\/p>\n

\n

 <\/p>\n

1\u00a0<\/sup>Pozitron-Diagnosztika K\u00f6zpont, Budapest<\/em><\/p>\n

2<\/sup>\u00a0Magyar Honv\u00e9ds\u00e9g Eg\u00e9szs\u00e9gu\u0308gyi K\u00f6zpont Honv\u00e9dk\u00f3rh\u00e1z, Pszichi\u00e1triai Oszt\u00e1ly, Budapest<\/em><\/p>\n

 <\/p>\n<\/div>\n

\n
\n

When facing comorbidity, effects of medicating one disorder on the other disease is a key question for the clinician. As depression influences both development and outcome of onco-logical diseases, early diagnosis and therapy, primarily with antidepressants, is of paramount importance. This paper gives a survey on the effects of antidepressants on comorbid mood disorders, on the course of cancerous diseases and on the tumor itself. Response to therapy is similar for patients with comorbid and primary depression, just as there is no significant difference in tolerability. Early studies have shown that antidepressants increase the risk of
tumor development, have negative effects on the outcome of oncological diseases and even increase mortality. However, recent epidemiological and clinical studies show opposing results and demonstrate beneficial action of antidepressants on various oncological diseases suchas gli\u00f3ma and hepatocellular cancer. Like any drug, antidepressants have effects not only on targets in the brain but also on other organs, hence on tumor tissues as well. Latest preclinical studies demonstrate that certain antidepressants facilitate apoptosis, autophagy of tumor cells and potentiate the efficacy of anticancer agents acting as chemosensitizers. Direct and indirect antitumor effects of antidepressants are proven, however, their clinical use requires
further studies focusing on the specificity of agents on different tumor types.
Keywords<\/strong>: comorbidity, oncological disease, depression, antidepressants<\/p>\n<\/div>\n<\/div>\n

[\/et_pb_toggle][et_pb_blurb title=”The role of positron emission tomography (PET) in tumor diagnostics and therapy monitoring” url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_kajary_honlapra.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”4.6.5″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_kajary_honlapra.pdf”]<\/p>\n

dr. Korn\u00e9lia Kaj\u00e1ry Ph.D.<\/p>\n

[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” hover_enabled=”0″ border_width_all=”0px” border_width_bottom=”1px” sticky_enabled=”0″]<\/p>\n

\n

The role of positron emission tomography (PET) in tumor diagnostics and therapy monitoring<\/h4>\n
\n

Korn\u00e9lia Kaj\u00e1ry , Sarolta Szekeres, M\u00e1t\u00e9 L\u00e1z\u00e1r, Andrea N\u00e9meth, Hajna Galg\u00f3czy, P\u00e9ter Moln\u00e1r and Zsolt Lengyel<\/p>\n

\n

 <\/p>\n

Pozitron-Diagnosztika K\u00f6zpont, Budapest<\/em><\/p>\n<\/div>\n

\n
\n

Positron emission tomography (PET) is a medical imaging method belonging to the realmof nuclear medicine. It has been a clinical research tool since the sixties but during the late nineties it became widely utilized in clinical practice too. PET technique requires special radioactive isotopes, which may be generated only in particle accelerators (cyclotrons) and their transport is limited owing to the short physical half-life. PET\/CT was born from the com-bination of PET and CT (computer tomography). The first combined PET\/CT scanner began to operate in 1998 and the method has been used in clinical practice since 2001. It is a hybrid (multi-modality) medical imaging equipment which can provide anatomical, morphologic (CT) and functional, metabolic information (PET) simultaneously. PET\/CT imaging has gained
clinical acceptance mainly in oncology \u2013 owing to the attributes of the most frequently used PET tracer, fluoro-deoxy glucose (FDG) \u2013 and in a lesser extent in neuropsychiatry and cardiol-ogy. The authors in this paper review the basics and key indications of the method, the wider used radiofarmacons, including potential neurological and psychiatric applications, and the possible causes of false positivity and false negativity.<\/p>\n

(Neuropsychopharmacol Hung 2018; 20(3): 99\u2013111)<\/em><\/p>\n

Keywords:<\/strong> positron emission tomography (PET), positron emission tomography\/computed tomography (PET\/CT), fluoro-deoxy glucose (FDG)<\/p>\n<\/div>\n<\/div>\n

[\/et_pb_toggle][et_pb_blurb title=”Chemobrain” url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_szentmartoni_honlapra.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”4.6.5″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/2018_09_szentmartoni_honlapra.pdf”]<\/p>\n

Gy\u00f6ngyv\u00e9r Szentm\u00e1rtoni 1<\/sup>, Zolt\u00e1n Makkos2<\/sup> \u00e9s Magdolna Dank1<\/sup><\/p>\n

[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” hover_enabled=”0″ border_width_all=”0px” border_width_bottom=”1px” sticky_enabled=”0″]<\/p>\n

\n

Gy\u00f6ngyv\u00e9r Szentm\u00e1rtoni 1<\/sup>, Zolt\u00e1n Makkos2<\/sup> \u00e9s Magdolna Dank1<\/sup><\/p>\n

\n

 <\/p>\n

1<\/sup>\u00a0Semmelweis Egyetem Onkol\u00f3giai K\u00f6zpont, Budapest<\/em><\/p>\n

2<\/sup>\u00a0Ny\u00edr\u0151 Gyula OPAI \u201eC\u201d Pszichi\u00e1triai Oszt\u00e1ly, Budapest<\/em><\/p>\n<\/div>\n

\n
\n

Over the past ten years, in oncology there is an increased interest in understanding the cognitive dysfunction caused by chemotherapy also known as chemobrain or chemofog. As a result of oncological therapies the number of survivors of malignant diseases has increased considerably, but the side effects also appear to be more prevalent and severe including per-sistent cognitive symptoms. Symptoms of\u00a0 hemobrain include memory impairment, loss of concentration, speech and psychomotor deceleration, attention and learning coordination problems, and disturbance of executive functions. The symptoms may be transient but are often long-lasting, the latter negatively affecting functionality and quality of life. Structural and functional imaging studies (MRI, fMRI, PET) and neuropsychological tests are not consistent in the diagnosis of chemobrain. Several factors are suspected leading to the appearance of symptoms, but the specific patomechanism is not yet known. Nutrition status, age, anemia,inflammatory cytokines, stress, and depression can all affect the quality of life and may be related to cognitive symptoms. Currently, there is no treatment strategy for preventing or al-leviating cognitive impairement related to chemobrain, and several pharmacotherapies are under investigation. Results imply that understanding the patomechanism of chemobrain can also yield a deeper understanding of cognitive dysfunction associated with depression.<\/p>\n

(Neuropsychopharmacol Hung 2018; 20(3): 112\u2013116)<\/em><\/p>\n

Keywords:<\/strong> chemobrain, chemofog, cognitive symptoms, oncotherapy, antidepressants<\/p>\n<\/div>\n

[\/et_pb_toggle][et_pb_blurb title=”FOLY\u00d3IRAT REFER\u00c1TUMOK” url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/folyref_honlapra.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”4.6.5″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xx-evfolyam-3-szam\/folyref_honlapra.pdf”]<\/p>\n

\n

L\u00e1szl\u00f3 P\u00e9ter<\/p>\n<\/div>\n

[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” hover_enabled=”0″ border_width_all=”0px” border_width_bottom=”1px” sticky_enabled=”0″]<\/p>\n

\n

Antiepileptikumok haszn\u00e1lata \u00e9s a demencia kialakul\u00e1s\u00e1nak kock\u00e1zata<\/strong><\/p>\n

Use of Antiepileptic Drugs and Dementia Risk; An Analysis of Finnish Health Register and German Insurance Data; Heidi Taipale, Willy Gomm, Karl Broich, Wolfgang Maier, Anna-Maija Tolppanen, Antti Tanskanen, Phil Lic, Jari Tijhonen, Sirpa Hartikainen, Britta Haenisch; J Am Geriatr Soc. 2018; 66(6): 1123-1129<\/p>\n

 <\/p>\n

Sz\u00edvm\u0171t\u00e9ten \u00e1tesett betegek k\u00f6r\u00e9ben a szelekt\u00edv szerotonin reuptake inhibitorok \u00e9s a szerotoninnoradrenalin reuptake inhibitorok haszn\u00e1lata nem mutatott \u00f6sszefu\u0308gg\u00e9st a kialakult v\u00e9rz\u00e9ssel \u00e9s a k\u00f6vetkezm\u00e9nyes transzf\u00fazi\u00f3val<\/strong><\/p>\n

Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors Are Not Associated With Bleeding or Transfusion in Cardiac Surgery Patients; Mark M Smith, Bradford B Smith, Brian D. Lahr, Gregory A Nuttall, William J. Mauermann, Timothy J. Weister, Joseph A. Dearani, David W. Barbara; Anesth Analg. 2018; 126(6): 1859-1866<\/p>\n<\/div>\n

[\/et_pb_toggle][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/05\/2018_09_borito_kicsi.jpg” url_new_window=”on” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” _builder_version=”4.6.5″ box_shadow_style=”preset3″][\/et_pb_image][\/et_pb_column][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Volume 20, Issue 3, September 2018G\u00e1bor Kov\u00e1cs A lapsz\u00e1m, amelyet kez\u00e9ben tart, vagy ak\u00e1r a k\u00e9perny\u0151j\u00e9n tanulm\u00e1nyoz a tisztelt olvas\u00f3, az onkol\u00f3giai \u00e9s pszichi\u00e1triai, d\u00f6nt\u0151en affekt\u00edv betegs\u00e9gek komorbidit\u00e1s\u00e1val, diagnosztikai \u00e9s ter\u00e1pi\u00e1s aspektusaival foglalkozik. A magyar szakirodalmat \u00e1ttekintve el\u00e9g kev\u00e9s tanulm\u00e1nyt tal\u00e1lunk, amely a \u201etesti\u201d \u00e9s \u201elelki\u201d betegs\u00e9gek \u00f6sszefu\u0308gg\u00e9s\u00e9vel foglalkozik, pedig \u00e1ltal\u00e1noss\u00e1gban a teljes popul\u00e1ci\u00f3 t\u00f6bb […]<\/p>\n","protected":false},"author":4,"featured_media":48294,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[57],"project_tag":[],"class_list":["post-48519","project","type-project","status-publish","has-post-thumbnail","hentry","project_category-neuropsychopharmacologia-hungarica-2-en"],"_links":{"self":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/48519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/comments?post=48519"}],"version-history":[{"count":10,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/48519\/revisions"}],"predecessor-version":[{"id":49530,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/48519\/revisions\/49530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media\/48294"}],"wp:attachment":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media?parent=48519"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_category?post=48519"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_tag?post=48519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}